With Oxlumo’s approval, Alnylam aims to speed access with new value-based pricing framework

With the approval of Oxlumo to treat primary hyperoxaluria, Alnylam is aiming to accelerate patient access to the ultra-rare disease therapy by building on the performance- and prevalence-based pricing strategy it had laid out for its first two approved drugs.

FDA approved Oxlumo lumasiran for primary hyperoxaluria type 1 (PH1) on Monday evening. The approval is the third in as many years for an RNAi therapy from Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) , and Oxlumo is the first targeted therapeutic for the indication. ...